Unlocking Pharmaceutical Advancements: The Role of 3-[(1S)-1-(Dimethylamino)ethyl]phenol
A pivotal intermediate shaping the future of neurodegenerative disease treatments.
Get a Quote & SampleProduct Core Value
![(1S)-1-(Dimethylamino)ethyl]phenol](https://www.nbinno.com/2025/webimg/gemini_688d3ff9ca2af_1754087417.png)
(1S)-1-(Dimethylamino)ethyl]phenol
This high-purity chemical intermediate is indispensable for the synthesis of Rivastigmine, a crucial medication for managing Alzheimer's and Parkinson's disease. Its precise stereochemistry is vital for the final drug's efficacy and safety, positioning it as a cornerstone in the production chain of these therapeutic agents.
- Discover the critical role of 3-[(1S)-1-(Dimethylamino)ethyl]phenol synthesis in advancing treatments for neurodegenerative disorders.
- Source high purity chemical intermediates from reliable suppliers to ensure the quality of your pharmaceutical products.
- Explore the advantages of using CAS 139306-10-8 intermediate in your drug development pipeline.
- Learn how partnering with a leading Rivastigmine intermediate manufacturer in China can optimize your supply chain.
Key Advantages Provided
Enhanced Therapeutic Efficacy
As a chiral pharmaceutical intermediate, its specific stereoisomer ensures the maximum therapeutic effect and safety profile in the final Rivastigmine tartrate product, directly impacting patient outcomes.
Stringent Quality Assurance
With purity levels of u226599% and low impurity content, this compound meets rigorous pharmaceutical standards, making it a reliable choice for demanding applications and ensuring batch-to-batch consistency.
Streamlined Manufacturing Processes
The compound's physical and chemical properties, such as its stable powder form, facilitate easier handling, storage, and integration into large-scale pharmaceutical manufacturing processes.
Key Applications
Rivastigmine Synthesis
The primary application of this vital intermediate is in the chemical synthesis of Rivastigmine, a cholinesterase inhibitor used to treat cognitive decline associated with Alzheimer's and Parkinson's diseases.
Alzheimer's Disease Treatment
By enabling the production of Rivastigmine, this intermediate plays an indirect but crucial role in the management of Alzheimer's disease symptoms, improving the quality of life for patients.
Parkinson's Disease Dementia Management
It is also essential for the synthesis of Rivastigmine used in treating dementia associated with Parkinson's disease, highlighting its broad impact on neurological health.
Chiral Drug Development
As a chiral compound, it serves as a model and essential component in the development of other stereospecific pharmaceuticals, advancing the field of chiral synthesis.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).